KB301
AXP000199.1 · Viral vector gene therapy
- Platform
- HSV-1 (replication-defective)
- Targets
- COL3A1
- Originator
- Jeune Aesthetics (Krystal Biotech)
- Sponsor
- Jeune Aesthetics (Krystal Biotech)
Names
Virus
- Role
- In vivo gene transfer
- Family
- Herpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- non replicating
- Modifications
- replication-defective, non-integrating HSV-1 backbone; two copies of COL3A1
- Transgenes
- COL3A1
- Route
- intradermal
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04540900 | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions | Active not recruiting | Phase 1 | 2020-10-07 | 2024-10-16 | 85 | Fine Lines; Skin Roughness; Skin Thickness; Wrinkle |
Recent changes
No changes recorded in its trials yet.
Notes
Intradermal replication-defective, non-integrating HSV-1 vector delivering two copies of COL3A1 to raise type III collagen in skin; phase 1 PEARL-1, NCT04540900, in aesthetic indications (lateral canthal lines, decollete wrinkles). Aesthetic rather than disease indication, but a human gene therapy in a registered trial, so in scope.
How to cite
KB301 (AXP000199.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000199.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.